Wilmington Savings Fund Society FSB Sells 115 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Wilmington Savings Fund Society FSB trimmed its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 6.4% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,695 shares of the biopharmaceutical company’s stock after selling 115 shares during the period. Wilmington Savings Fund Society FSB’s holdings in Regeneron Pharmaceuticals were worth $1,207,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in REGN. Mizuho Securities USA LLC lifted its position in shares of Regeneron Pharmaceuticals by 625.5% during the third quarter. Mizuho Securities USA LLC now owns 59,341 shares of the biopharmaceutical company’s stock valued at $62,382,000 after buying an additional 51,162 shares during the last quarter. Principal Financial Group Inc. raised its stake in shares of Regeneron Pharmaceuticals by 1.7% during the 3rd quarter. Principal Financial Group Inc. now owns 173,092 shares of the biopharmaceutical company’s stock worth $181,961,000 after acquiring an additional 2,828 shares in the last quarter. Simplify Asset Management Inc. lifted its position in Regeneron Pharmaceuticals by 50.8% during the third quarter. Simplify Asset Management Inc. now owns 9,591 shares of the biopharmaceutical company’s stock valued at $10,082,000 after acquiring an additional 3,231 shares during the last quarter. Golden State Equity Partners boosted its stake in Regeneron Pharmaceuticals by 1,479.1% in the fourth quarter. Golden State Equity Partners now owns 1,358 shares of the biopharmaceutical company’s stock valued at $967,000 after acquiring an additional 1,272 shares in the last quarter. Finally, Catalytic Wealth RIA LLC purchased a new position in Regeneron Pharmaceuticals in the third quarter worth $1,334,000. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on REGN. Robert W. Baird decreased their price objective on Regeneron Pharmaceuticals from $940.00 to $759.00 and set a “neutral” rating for the company in a report on Wednesday, February 5th. Leerink Partners raised Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and raised their price target for the stock from $762.00 to $834.00 in a report on Wednesday, February 5th. Evercore ISI dropped their price target on Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating on the stock in a research note on Thursday, October 24th. Bernstein Bank decreased their price objective on shares of Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research report on Tuesday, February 4th. Finally, UBS Group downgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $1,130.00 to $738.00 in a research report on Thursday, January 16th. One analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have given a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $973.13.

Regeneron Pharmaceuticals Stock Performance

NASDAQ REGN opened at $710.00 on Monday. The company has a current ratio of 4.73, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a twelve month low of $642.00 and a twelve month high of $1,211.20. The stock has a 50-day moving average of $715.81 and a 200 day moving average of $910.08. The stock has a market capitalization of $78.02 billion, a price-to-earnings ratio of 18.55, a PEG ratio of 2.38 and a beta of 0.08.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $11.21 by $0.86. The firm had revenue of $3.79 billion for the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The business’s revenue was up 10.3% on a year-over-year basis. During the same quarter last year, the firm posted $11.86 EPS. Sell-side analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 36.67 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th will be given a $0.88 dividend. The ex-dividend date is Thursday, February 20th. This represents a $3.52 annualized dividend and a dividend yield of 0.50%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 2.30%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.